Neurocrine Biosciences, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2014 | — | $208.7M | $31.0M |
| FY2015 | — | $424.5M | $74.2M |
| FY2016 | — | $314.9M | $83.3M |
| FY2017 | — | $372.2M | $254.7M |
| FY2018 | — | $480.8M | $141.7M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2014 | — | $208.7M | $31.0M |
| FY2015 | — | $424.5M | $74.2M |
| FY2016 | — | $314.9M | $83.3M |
| FY2017 | — | $372.2M | $254.7M |
| FY2018 | — | $480.8M | $141.7M |